600750 Jiangzhong Pharmaceutical
- 22.10
- +0.04+0.18%
Jiangzhong Pharmaceutical News
Jiangzhong Pharmaceutical (600750): Stock-based Incentive raises performance assessment targets, integration of internal and external resources is expected to accelerate.
Event: On January 1, the company announced the second phase of the restricted Stocks incentive plan (revised draft), intending to grant no more than 6.877 million shares to the incentivized parties, accounting for 1.09% of the total share capital, with no more than 170 incentivized parties.
Express News | This week, 10 listed companies announced the details related to share repurchase and additional loan disclosures. Hangzhou Hikvision Digital Technology plans to use its own funds and special loans of 2 billion to -2.5 billion yuan to repurchase shares.
Jiangzhong Pharmaceutical (600750.SH): The controlling Shareholder has obtained a commitment letter for a special loan for Shareholding in Stocks.
On December 10, Gelonghui reported that Jiangzhong Pharmaceutical (600750.SH) announced that on December 9, 2024, it received a notice from its controlling shareholder China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "China Resources Jiangzhong"). China Resources Jiangzhong has recently obtained a loan commitment letter issued by the Nanchang Donghu Branch of the Industrial And Commercial Bank Of China (hereinafter referred to as "ICBC Nanchang Donghu Branch"). ICBC Nanchang Donghu Branch intends to provide a loan limit of no more than 0.084 billion yuan to China Resources Jiangzhong for its shareholding increase plan, with a loan term of 12 months.
Express News | Jiangzhong Pharmaceutical: The controlling shareholder China Resources Jiangzhong has obtained a loan limit of up to 0.084 billion yuan for Shareholding in the company's shares.
Express News | Under the guidance of market cap management policies, state-owned enterprises are intensively buying back and increasing their shareholding.
Jiangzhong Pharmaceutical (600750): The leading OTC gastrointestinal category leader in China.
Initiate coverage of Jiangzhong Pharmaceutical for the first time with a "buy" rating and a target price of 28.91 yuan. The company is a business unit under China Resources Group that focuses on chinese patent medicine and health products. In recent years, through organic growth and external expansion, OTC revenue growth has outperformed the industry.
China Resources Pharmaceutical Group's Unit Posts Higher Profit in January-September
Jiangzhong Pharmaceutical (600750): The profit margin in the third quarter increased steadily, with the health business awaiting recovery.
Event: On October 25th, the company released the third quarter report of 2024. In the first three quarters of 2024, the company achieved revenue of 2.972 billion yuan (-8.19% year-on-year), and achieved a net income attributable to the parent company of 0.634 billion yuan.
Jiangzhong Pharmaceutical Report for the Third Quarter of 2024
Jiangzhong Pharmaceutical Sees Profit Growth Amid Revenue Dip
ChinahTa Pharmaceuticals (03320): jiangzhong pharmaceutical achieved a net income of 0.684 billion yuan in the first three quarters, an increase of 8.98% year-on-year.
Chinare Pharma (03320) announced that on October 25, 2024, jiangzhong pharmaceutical released its financial results for the year ending 202...
Express News | Jiangzhong Pharmaceutical Co., Ltd. intends to acquire 51% equity of Jiangzhong Herbal Pieces for 86.1238 million yuan.
CCTV+: Explore the Wizard of Oz in Jiangzhong Pharmaceutical Valley
Jiangzhong Pharmaceutical (600750): Responding to policy guidance, shareholding demonstrates confidence in development.
Event: On October 21, 2024, the company announced a plan for the controlling shareholder to increase its holdings in the company. The controlling shareholder, China Resources Jiangzhong, intends to trade through the Shanghai Stock Exchange trading system within 12 months from the date of disclosure in the announcement.
Chinares Pharma (03320.HK) subsidiary Jiangzhong Pharmaceutical's shareholders plan to increase their shareholding by up to 0.12 billion RMB.
Chinare Pharma (03320.HK) announced that the Shanghai A-listed subsidiary Jiangzhong Pharmaceutical's major shareholder, Huarun Jiangzhong, plans to increase its shareholding in Jiangzhong Pharmaceutical within twelve months from today, with a total amount of no less than 60 million RMB and not more than 0.12 billion RMB. Currently, Jiangzhong Pharmaceutical is held by the company's non-wholly-owned subsidiary Huarun Jiangzhong with a 43.09% stake, and the group actually controls around 26.09% of Jiangzhong Pharmaceutical.
Express News | Jiangzhong Pharmaceutical: The controlling shareholder plans to increase shareholding by 0.06 billion yuan to -0.12 billion yuan.
jiangzhong pharmaceutical (600750.SH) plans to distribute 0.5 yuan per share for the half year, ex-dividend and ex-dividend on October 10th.
Jiangzhong Pharmaceutical (600750.SH) announced that it plans to distribute a cash dividend of 0.5 yuan per share for the first half of 2024...
Jiangzhong Pharmaceutical (600750): H1 performance remains stable, OTC gross margin improves.
Event: The company recently released the 2024 interim report. In the first half of 2024, the company achieved revenue of 2.173 billion yuan (-8.02%), net income attributable to the parent company of 0.489 billion yuan (+8.66%); among them, 2024
Jiangzhong Pharmaceutical's H1 Profit Rises 9%, Revenue Slides 8%
Jiangzhong Pharmaceutical (600750): Stable performance growth, launching mid-term dividends.
Event: On August 21, 2024, the company released its mid-year report for 2024. In the first half of 2024, the company achieved revenue of 2.173 billion yuan, a year-on-year decline of 8.02%; achieved net income attributable to shareholders of 0.489 billion yuan.
No Data
